KOD News and Press, Kodiak Sciences Inc From 05/11/21

Kodiak Sciences (KOD) has extended the intra-day losses yesterday with a ~10.6% drop in the pre-market.In a regulatory filing, the company has announced that ~14.0M shares will be sold by the selling stockholders from time to time.The offer includes ~150.0K shares of its common stoc...

Kodiak Sciences ([[KOD]] -13.1%) met analyst expectations with its Q1 financials for 2021. But the stock is trading sharply lower after the company updated its clinical trial progress and the path for licensure for KSI-301.Kodiak was advancing KSI-301 in four pivotal studies to...

Shares of Kodiak Sciences (NASDAQ: KOD) were tumbling 11.1% lower as of 12:07 p.m. EDT on Monday. The decline came after the company provided its first-quarter update. Kodiak reported a net loss in Q1 of $0.98 per share with no revenue. That bottom-line result was a little worse...

Gainers: Protagenic Therapeutics (PTIX) +44%, Cue Biopharma CUE +36%, Obalon Therapeutics (OBLN) +28%, Soliton SOLY +24%, Precipio (PRPO) +20%.Losers: Insmed INSM -17%, Soligenix (SNGX) -17%, Kodiak Sciences (KOD) -14%, Dynavax ...

Kodiak Sciences Announces First Quarter 2021 Financial Results and Recent Business Highlights PR Newswire PALO ALTO, Calif. , May 10, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing an...

Ocular Therapeutix is a multi-bagger stock with substantial upsides. Despite over two-fold gains, I believe it can appreciate higher due to pending catalysts. Dextenza is poised to gain the label expansion for the treatment of allergic conjunctivitis. In the longer horizon, Ocular...

OCUL has an approved product set and a candidate targeting wet AMD. Phase 1 data in a small patient set saw strong data with long durability of therapy. However, competition is highly differentiated and OCUL is too early stage to position itself properly. For further details...

The following slide deck was published by Kodiak Sciences Inc. in conjunction with this event. For further details see: Kodiak Sciences (KOD) Presents At Barclays Global Healthcare Conference - Slideshow

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The energy and shipping markets take center stage next week as the drama in the Suez Canal continues to play out and OPE...

Kodiak Sciences is expected to have three trial readouts in 2022 with use of its drug KSI-301. If all studies end up being successful, then 3 BLA filings would happen. The first most important trial readout would be from the phase 2b/3 DAZZLE study using KSI-301 to treat patients with...